» Articles » PMID: 27462115

Identification of Reversible Disruption of the Human Blood-Brain Barrier Following Acute Ischemia

Overview
Journal Stroke
Date 2016 Jul 28
PMID 27462115
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Animal models of acute cerebral ischemia have demonstrated that diffuse blood-brain barrier (BBB) disruption can be reversible after early reperfusion. However, irreversible, focal BBB disruption in humans is associated with hemorrhagic transformation in patients receiving intravenous thrombolytic therapy. The goal of this study was to use a magnetic resonance imaging biomarker of BBB permeability to differentiate these 2 forms of BBB disruption.

Methods: Acute stroke patients imaged with magnetic resonance imaging before, 2 hours after, and 24 hours after treatment with intravenous tissue-type plasminogen activator were included. The average BBB permeability of the acute ischemic region before and 2 hours after treatment was calculated using a T2* perfusion-weighted source images. Change in average permeability was compared with percent reperfusion using linear regression. Focal regions of maximal BBB permeability from the pretreatment magnetic resonance imaging were compared with the occurrence of parenchymal hematoma (PH) formation on the 24-hour magnetic resonance imaging scan using logistic regression.

Results: Signals indicating reversible BBB permeability were detected in 18/36 patients. Change in average BBB permeability correlated inversely with percent reperfusion (P=0.006), indicating that early reperfusion is associated with decreased BBB permeability, whereas sustained ischemia is associated with increased BBB disruption. Focal regions of maximal BBB permeability were significantly associated with subsequent formation of PH (P=0.013).

Conclusions: This study demonstrates that diffuse, mild BBB disruption in the acutely ischemic human brain is reversible with reperfusion. This study also confirms prior findings that focal severe BBB disruption confers an increased risk of hemorrhagic transformation in patients treated with intravenous tissue-type plasminogen activator.

Citing Articles

5-(3-(-(Carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1-pyrrole-2-carboxylic acid as a Keap1-Nrf2 inhibitor for cerebral ischemia/reperfusion injury treatment.

Cairang N, Wu Y, Zhi S, Tang J, Tie X, Zhan D RSC Adv. 2025; 15(2):1052-1059.

PMID: 39807188 PMC: 11726444. DOI: 10.1039/d4ra06512c.


Blood-brain barrier breakdown in brain ischemia: Insights from MRI perfusion imaging.

Sasannia S, Leigh R, Bastani P, Shin H, van Zijl P, Knutsson L Neurotherapeutics. 2024; 22(1):e00516.

PMID: 39709246 PMC: 11840350. DOI: 10.1016/j.neurot.2024.e00516.


Blood-brain barrier profile pretreatment is associated with hemorrhagic transformation after endovascular reperfusion.

Leigh R, Seners P, Rousseau V, Christensen S, Albucher J, Drif A Ann Clin Transl Neurol. 2024; 11(12):3292-3299.

PMID: 39462241 PMC: 11651177. DOI: 10.1002/acn3.52236.


Blood-Brain Barrier Disruption and Imaging Assessment in Stroke.

Liang Y, Jiang Y, Liu J, Li X, Cheng X, Bao L Transl Stroke Res. 2024; .

PMID: 39322815 DOI: 10.1007/s12975-024-01300-6.


Blood-brain barrier disruption and hemorrhagic transformation in acute stroke before endovascular reperfusion therapy.

Liang Y, Yu Y, Liu J, Li X, Chen X, Zhou H Front Neurol. 2024; 15:1349369.

PMID: 38756220 PMC: 11097340. DOI: 10.3389/fneur.2024.1349369.


References
1.
Shah S, Luby M, Poole K, Morella T, Keller E, Benson R . Screening with MRI for Accurate and Rapid Stroke Treatment: SMART. Neurology. 2015; 84(24):2438-44. PMC: 4478034. DOI: 10.1212/WNL.0000000000001678. View

2.
Leigh R, Jen S, Varma D, Hillis A, Barker P . Arrival time correction for dynamic susceptibility contrast MR permeability imaging in stroke patients. PLoS One. 2013; 7(12):e52656. PMC: 3527589. DOI: 10.1371/journal.pone.0052656. View

3.
Leigh R, Jen S, Hillis A, Krakauer J, Barker P . Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke. 2014; 45(7):2030-5. PMC: 4120660. DOI: 10.1161/STROKEAHA.114.005249. View

4.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D . Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136):1245-51. DOI: 10.1016/s0140-6736(98)08020-9. View

5.
Rozanski M, Ebinger M, Schmidt W, Hotter B, Pittl S, Heuschmann P . Hyperintense acute reperfusion marker on FLAIR is not associated with early haemorrhagic transformation in the elderly. Eur Radiol. 2010; 20(12):2990-6. DOI: 10.1007/s00330-010-1881-9. View